Publications by authors named "S Pledge"

Claim this Profile
O
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Paul Tappenden, Sue Harnan, Shijie Ren, Praveen Thokala, Ruth Wong, Simon Pledge

Pharmacoeconomics· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
R M Glasspool, R Brown, M E Gore, G J S Rustin, I A McNeish, S Pledge

Br J Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.
S Banerjee, G Rustin, J Paul, C Williams, S Pledge

Ann Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modern chemotherapy management of recurrent ovarian cancer: a multicentre study.
S Chan, M Griffin, J Stewart, K Gregory, A Hughes, S Pledge

Clin Oncol (R Coll Radiol)· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence of thyroid abnormalities in adults irradiated for lymphoma.
S H Ding, S D Pledge, B J Harrison, R J Peck, M J Bull

Int J Oncol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis